China Biologic Products, Inc. (NASDAQ:CBPO) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Monday.

According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “

Other analysts have also recently issued research reports about the stock. Jefferies Group LLC reaffirmed a “buy” rating on shares of China Biologic Products in a research note on Friday. Goldman Sachs Group, Inc. (The) started coverage on shares of China Biologic Products in a research note on Tuesday, May 30th. They set a “neutral” rating on the stock. Finally, BidaskClub cut shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Sunday, July 16th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. China Biologic Products presently has an average rating of “Hold” and an average price target of $132.00.

Shares of China Biologic Products (NASDAQ:CBPO) traded down 1.30% on Monday, reaching $95.78. The company’s stock had a trading volume of 196,125 shares. China Biologic Products has a 52-week low of $95.43 and a 52-week high of $137.38. The firm has a 50 day moving average of $105.95 and a 200 day moving average of $108.21. The company has a market cap of $2.61 billion, a PE ratio of 24.93 and a beta of 1.70.

China Biologic Products (NASDAQ:CBPO) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.05. The firm had revenue of $89.28 million for the quarter, compared to analysts’ expectations of $97.33 million. China Biologic Products had a net margin of 31.55% and a return on equity of 21.86%. The company’s revenue was down 2.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.26 earnings per share. Analysts predict that China Biologic Products will post $4.95 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “China Biologic Products, Inc. (NASDAQ:CBPO) Downgraded to “Sell” at Zacks Investment Research” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/08/07/china-biologic-products-inc-nasdaqcbpo-downgraded-to-sell-at-zacks-investment-research.html.

In related news, insider Zhijing Cbpo Liu sold 7,500 shares of the business’s stock in a transaction on Tuesday, May 9th. The shares were sold at an average price of $116.49, for a total value of $873,675.00. Following the sale, the insider now owns 10,969 shares of the company’s stock, valued at $1,277,778.81. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 2.73% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of China Biologic Products by 694.1% in the first quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock valued at $151,007,000 after buying an additional 1,318,183 shares in the last quarter. FMR LLC boosted its stake in shares of China Biologic Products by 27.5% in the first quarter. FMR LLC now owns 1,880,549 shares of the biopharmaceutical company’s stock valued at $188,300,000 after buying an additional 406,105 shares in the last quarter. Hermes Investment Management Ltd. boosted its stake in shares of China Biologic Products by 91.6% in the first quarter. Hermes Investment Management Ltd. now owns 631,224 shares of the biopharmaceutical company’s stock valued at $63,204,000 after buying an additional 301,828 shares in the last quarter. Macquarie Group Ltd. acquired a new stake in shares of China Biologic Products during the first quarter valued at $27,324,000. Finally, Artisan Partners Limited Partnership boosted its stake in shares of China Biologic Products by 103.2% in the first quarter. Artisan Partners Limited Partnership now owns 395,578 shares of the biopharmaceutical company’s stock valued at $39,609,000 after buying an additional 200,868 shares in the last quarter. 74.09% of the stock is currently owned by institutional investors.

About China Biologic Products

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment.

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.